MannKind's Pediatric Expansion: A New Era for Afrezza
Decision brief
Answer first · skim in under a minute
MannKind's recent approval of Afrezza for pediatric use marks a significant milestone. This article explores the implications for investors and pharma teams.
On May 29, 2026, the FDA approved Afrezza inhaled mealtime insulin for children and adolescents aged 6 and older with type 1 or type 2 diabetes. The expansion rests on Phase 3 INHALE-1 (NCT04974528) and closes MannKind’s remaining postmarketing requirement from the 2014 adult approval.
Contents9 sections
Key Takeaways
- FDA approved Afrezza for patients aged 6+ with diabetes on May 29, 2026.
- Supportive evidence: Phase 3 INHALE-1 (NCT04974528), including a 26-week randomized phase and extension.
- MannKind 8-K: pediatric sBLA fulfilled the last postmarketing requirement from the June 27, 2014 letter.
- Company estimate: more than 350,000 U.S. children and adolescents live with diabetes.
What did the FDA approve for Afrezza on May 29, 2026?
The FDA approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes. The product remains a rapid-acting inhaled human insulin for mealtime use via MannKind’s Technosphere delivery system.
MannKind disclosed the decision the same day in a Form 8-K filed with the U.S. SEC and in a GlobeNewswire release.
How does INHALE-1 support the pediatric Afrezza label?
INHALE-1 (NCT04974528) is a Phase 3, open-label, randomized trial of Afrezza versus rapid-acting insulin analog injections, both with basal insulin, in pediatric subjects with type 1 or type 2 diabetes. The registry lists a 26-week primary treatment phase and a 26-week extension in which subjects receive Afrezza through week 52.
Per ClinicalTrials.gov NCT04974528, eligible ages were 4 to under 18 years; primary completion was October 3, 2024, and study completion April 29, 2025. MannKind said the pediatric approval is supported by INHALE-1 plus longer-term inhaled-insulin safety and exposure data.
Label history and postmarketing closure
Afrezza was first FDA-approved on June 27, 2014, for adults. The May 2026 action expands the labeled population to include pediatric patients aged 6 and older. The updated prescribing information is published on FDA’s label repository as NDA 022472 supplement 027.
- Adult approval date: June 27, 2014.
- Pediatric expansion announced: May 29, 2026.
- Labeled ages after expansion: 6 years and older.
- Postmarketing: FDA stated the pediatric sBLA fulfilled the last remaining requirement from the 2014 letter, per MannKind’s 8-K.
Reviewers can cross-check the current labeled indication in the FDA accessdata label PDF (022472s027).
Commercial and access implications for diabetes teams
MannKind’s 8-K cites more than 350,000 U.S. children and adolescents living with diabetes, most with type 1 disease requiring lifelong insulin. For payers and specialty pharmacy, the practical change is a needle-free mealtime option alongside multiple daily injections and pumps—subject to prior authorization, spirometry screening for chronic lung disease, and smoking contraindications already on the adult label.
APAC market-access teams should treat the U.S. pediatric label as a regulatory precedent, not an automatic ex-U.S. approval. Local filings still need regional dossiers, pediatric plans, and reimbursement submissions.
Competitive intelligence should separate adult Afrezza share trends from incremental pediatric uptake. School nurse protocols, caregiver training on inhaler technique, and basal insulin pairing will shape real-world persistence more than the headline approval date alone.
What remains unproven
Company materials do not republish full INHALE-1 HbA1c point estimates in the 8-K summary used here. Analysts should pull primary efficacy tables from the clinical study report or peer-reviewed publication before modeling superiority claims. Lung-function monitoring, hypoglycemia rates, and real-world adherence in school settings remain key post-approval questions.
Until peer-reviewed INHALE-1 publications and the final FDA review package are fully digested, avoid extrapolating adult onset-of-action marketing claims into pediatric dosing algorithms without clinician oversight.
Related NovaPharma coverage
- FDA Approves MannKind's Afrezza for Pediatric Diabetes Patients
- FDA expands Tzield to certain pediatric patients with recent Stage 3 T1D
- Health News Round Up: Diabetes, Vaping, and Biologics
Frequently Asked Questions
When did FDA approve Afrezza for pediatric patients?
On May 29, 2026, the FDA approved Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 or type 2 diabetes, expanding the adult indication first approved in June 2014.
What trial supported the Afrezza pediatric label?
The pivotal Phase 3 INHALE-1 study (NCT04974528) compared Afrezza plus basal insulin with rapid-acting insulin analog injections plus basal insulin in pediatric subjects, with a 26-week primary phase and a 26-week extension.
Did the pediatric sBLA close Afrezza postmarketing requirements?
MannKind’s May 29, 2026 Form 8-K states the FDA said the pediatric supplemental biologics license application fulfilled the last remaining postmarketing requirement for Afrezza from the June 27, 2014 approval letter.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Afrezza.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
